Research and Markets (http://www.researchandmarkets.com/research/jnhh2r/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Allergic Conjunctivitis Overview
  4. Therapeutics Development
  5. Pipeline Products for Allergic Conjunctivitis - Overview
  6. Allergic Conjunctivitis - Therapeutics under Development by Companies
  7. Allergic Conjunctivitis - Pipeline Products Glance
  8. Late Stage Products
  9. Clinical Stage Products
  10. Early Stage Products
  11. Allergic Conjunctivitis - Products under Development by Companies
  12. Allergic Conjunctivitis - Companies Involved in Therapeutics Development
  • Accolade Pharma LLC
  • Akari Therapeutics, Plc
  • Aldeyra Therapeutics, Inc.
  • Allergan Plc
  • Eleven Biotherapeutics Inc.
  • Griffin Discoveries BV
  • NicOx S.A.
  • Ocular Therapeutix, Inc.
  • Ohr Pharmaceutical Inc.
  • Oxagen Limited
  • Sylentis S.A.
  • Xencor, Inc.

For more information visit http://www.researchandmarkets.com/research/jnhh2r/allergic